Category Archives: Patents

Subscribe to Patents RSS Feed

Belkin International, Inc. v. Kappos – A Cautionary Tale in the Intricate Arena of Inter Partes Reexamination

By Michael Murphy and Martin Bader On Tuesday of last week, the Federal Circuit held that a party bringing a request for inter-partes reexamination may not appeal a decision by the Director of the U.S. Patent and Trademark Office that certain prior art does not raise a substantial new question of patentability. See Belkin International, … Continue Reading

What You Need to Know About the New Inter Partes Review Process

By Daniel Yannuzzi On September 16th, 2012, new rules go into effect for post-grant proceedings for review of United States Patents. Among these are rules for post-grant review of issued patents, inter partes review and transitional post-grant review proceeding for covered business method patents. This article looks at the new requirements for inter partes review.… Continue Reading

What You Need to Know About the New Post-Grant Review Process for U.S. Patents

By Daniel Yannuzzi On September 16th, 2012, new rules go into effect for post-grant proceedings for review of United States Patents. Among these are rules for post-grant review of issued patents, inter partes review and transitional post-grant review proceedings for covered business-method patents. This article looks at the new requirements for post-grant review.… Continue Reading

Federal Circuit Declines to Adopt Test for Patent Eligibility Set Forth in CLS Bank

By Martin Bader and Matthew M. Mueller A three judge panel (Lourie*, Prost, Wallach) of the Federal Circuit recently handed down the Federal Circuit’s second decision in a month on patent eligibility under 35 U.S.C. §101. In a unanimous decision, the court in Bancorp Services, L.L.C. v. Sun Life Assurance Company of Canada (U.S.) (No. … Continue Reading

New USPTO Satellite Offices Target Centers of Innovation

By Nathaniel Bruno and Ali Hossein-Khan-Tehrani [1] While the United States Patent and Trademark Office (“USPTO”) has long been recognized as the U.S. government’s primary mechanism for encouraging and rewarding innovation by individuals, it has recently engaged in a concentrated season of internal administrative innovation. The Leahy-Smith America Invents Act (“AIA”), signed into law on … Continue Reading

Calcar and Thorner: Attempting to Reconcile the Federal Circuit’s Claim Construction Jurisprudence

By Nam Kim and Martin Bader In Thorner v. Sony Computer Entertainment America, LLC, 669 F.3d 1362 (Fed. Cir. 2012) (Moore, Rader & Aiken (D. Or. sitting by designation)), the Federal Circuit explained that, under Phillips, a claim term is given its ordinary and customary meaning as understood by a person of ordinary skill in … Continue Reading

CLS Bank: The patent eligibility of computerized trading platforms for exchanging obligations

By Barry Wilson and Martin Bader On July 9, 2012, a three judge panel of the Federal Circuit in CLS Bank International v. Alice Corporation (Appeal No. 2011-1301) ("CLS Bank"), decided a case of patent eligibility under 35 U.S.C. § 101. In a split decision, the panel reversed the district court’s finding that three Alice Corporation patents claiming a computerized … Continue Reading

Supreme Court confirms that generic drug manufacturers can challenge brand-name use-code descriptions in patent litigation

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S 566 U.S. ___, 132 S. Ct. 1670 (Apr. 17, 2012) By Nagendra Setty and Bill Blonigan The Hatch-Waxman Act Congress designed the Hatch-Waxman Act (codified at 21 U.S.C. § 355(b), (j), (l) and 35 U.S.C. §§ 156, 271, and 282) to inspire medical innovation by giving medical-device … Continue Reading

Courts to play greater role moderating enhanced damages for willful patent infringement

Bard Peripheral Vascular, Inc. v. W.L. Gore & Associates, Inc. (Fed. Cir. June 14, 2012) By Martin Bader and Bill Blonigan In this medical-device patent-infringement action, an Arizona federal jury found that W.L. Gore willfully infringed Bard’s Prosthetic Vascular Graft patent. The District Court then decided to double the jury’s $185.6 million damages award. Gore … Continue Reading

Is A Defendant A Willful Patent Infringer? Trial Courts Must Decide Whether The Actions Are Objectively Reasonable

By Mark McGrath The Federal Circuit’s recent decisions have sought to address a number of issues relating to damages in patent cases. In its recent decision in Bard Peripheral Vascular, Inc. v. W.L. Gore & Associates, Inc., No. 2010-1510, ___ F.3d ___ (Fed. Cir. June 14, 2012), available at http://www.cafc. uscourts.gov/images/stories/opinionsorders/ 10-1510.pdf (“Bard”), the Federal … Continue Reading

Section viii Statements — Still A Viable Route to Generic Approval Where the Application Is Not Claimed in an Orange Book Patent

By Nagendra Setty and Mark E. McGrath In its recent decision in AstraZeneca Pharmaceuticals LP v. Apotex Corp., Nos. 2011-1182 – 2011-1190 (Fed. Cir. Feb. 9, 2012) (hereinafter the “AstraZeneca Decision”) (Rader*, Bryson & Linn), the Federal Circuit affirmed a District of Delaware decision dismissing an infringement case for failure to state a claim, pursuant … Continue Reading

Supreme Court Holds That a Law of Nature Applied Using Known and Obvious Steps Is Not Patent Eligible

By Kevin Capps On March 20, 2012, the Supreme Court issued its much-anticipated decision in Mayo Collaborative Services, DBA Mayo Medical Laboratories, et al. v. Prometheus Laboratories, Inc., with potentially far-reaching ramifications for pharmaceutical and biotechnology companies, particularly those developing diagnostic methods and assays.… Continue Reading

Federal Circuit Narrows Claim Construction Options in Game Controller Suit

By Ryan Lindsey and Nick Setty In Thorner v. Sony Computer Entertainment America, LLC (Case No. 2011-1114, Feb. 1, 2012) (Moore*, Rader & Aiken (D. Or. sitting by designation)), the Federal Circuit reiterated the prohibition against importing limitations from the specification and reversed a district court construction depending from consistent uses of the disputed phrase in … Continue Reading

Federal Circuit Holds that “Isolated DNA Molecules” Are Patentable Subject Matter and Method Claims Merely “Comparing” or “Analyzing” Are Not

The Federal Circuit issued its much-anticipated decision in The Association for Molecular Pathology v. United States Patent and Trademark Office on July 29, 2011. The case concerns Myriad Genetics, Inc. and its patents covering two “isolated” human genes, BRCA1 and BRCA2.… Continue Reading

Supreme Court Rules That Knowledge Of Patent Is Required For Liability For Inducing Patent Infringement, But Willful Blindness Is Enough

Under section 271(b) of the Patent Act, a defendant in a patent infringement lawsuit may be held liable for inducing the infringement of a patent, i.e., causing another person to directly infringe a patent. However the language of the statute is not clear as to what conduct or intent is required for one to be … Continue Reading

Patent Reform

The Senate passed their version of a Patent Reform Bill (Senate Bill No. S. 23), on March 8, 2011 by a wide 95-5 margin. The bill makes significant changes, most notably including a first-inventor-to-file system, and an enhanced post-grant review procedures that will be conducted within the USPTO. There are 26 sections to the Senate bill.… Continue Reading

Trademarks In The Veldt: Do Virtual Lawyers Dream Of Electric Trademarks?

In Neal Stephenson’s 1992 science fiction novel, Snow Crash, humans interact as avatars in the “Metaverse,” the collective product of online shared three-dimensional space.[1] As imagined by Stephenson, this “Metaverse” has been created by all virtual worlds[2] – it is an augmented and enhanced physical reality, a physically persistent virtual space.[3] The novel is set … Continue Reading

Adjusting the Inequitable Conduct Doctrine: Federal Circuit Hears Oral Arguments En Banc in Therasense

By Gray M. Buccigross On November 9, 2010, the Federal Circuit, sitting en banc, heard oral arguments in Therasense, Inc. v. Becton, Dickinson & Co., regarding the legal tests to be applied in determining whether a patent is unenforceable due to inequitable conduct. This has been a controversial issue over the last several years among … Continue Reading

United States Weighs in on Myriad Genetics Case

On Friday, October 29, 2010, the United States submitted an amicus curiae brief in the Myriad Genetics, Inc. case. (The Association for Molecular Pathology, et al. v. Myriad Genetics, Inc., Federal Circuit Case No. 2010-1406.) Myriad Genetics holds several patents covering genomic materials relating to the human Breast Cancer Susceptibility Genes 1 and 2. A … Continue Reading

Supreme Court Rejects Bilski Claims, Overturns “Machine-or-Transformation” Requirement for Patent Eligibility of Processes

This morning, in a highly anticipated decision, a fractured Supreme Court affirmed the Federal Circuit’s judgment in Bilski v. Kappos. The Court unanimously upheld the rejection of Bilski’s patent claims, which concerned a process for hedging against the risk of price changes in the energy market. But the Court split on the grounds for rejecting … Continue Reading
LexBlog

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.

Agree